此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估IPS101A在帕金森病患者中的安全性、疗效和药代动力学的1期临床试验

2026年11月3日 更新者:Innopeutics Corporation

评估腺相关病毒(AAV)基因治疗产品IPS101A在Hoehn-Yahr分期4-5级、确诊超过10年且所有可用单药或联合疗法均无法控制的帕金森病患者中的安全性、疗效及药代动力学的剂量递增、单中心、开放标签1期临床试验

The purpose of this study is to evaluate the dose-related safety and tolerability of IPS101A, an adeno-associated virus (AAV) gene therapy, in patients with Parkinson's disease who exhibit severe functional impairment corresponding to Hoehn & Yahr stages 4-5 and whose symptoms are not adequately controlled despite all available monotherapy and combination therapy options. In addition, the study aims to assess the maximum tolerated dose (MTD) of IPS101A, as well as its preliminary efficacy and pharmacokinetic (PK) characteristics.

研究概览

地位

招聘中

干预/治疗

研究类型

介入性

注册 (估计的)

6

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Seoul、韩国
        • 招聘中
        • Severance Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

50年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Subjects who have a diagnosis of Parkinson's disease that meets the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria at the time of the Screening Visit.
  2. Male or female subjects aged 50 to 80 years (inclusive) at the time of providing written informed consent, with a documented diagnosis of Parkinson's disease.
  3. Subjects with a duration of Parkinson's disease of at least 10 years prior to the Screening Visit, based on medical history and/or medical records.
  4. Subjects with Parkinson's disease that is inadequately controlled despite all available standard-of-care treatments, including monotherapy or combination therapy, as determined by the Investigator.
  5. Subjects with a Hoehn & Yahr stage of 4 or 5 in the off state at the Screening Visit.

Exclusion Criteria:

  1. Subjects with Parkinson's disease dementia (PDD) who meet the diagnostic criteria established by the Movement Disorder Society (MDS) Task Force, as determined by the Investigator at Screening.
  2. Subjects with a Korean Mini-Mental State Examination (K-MMSE) score ≤ 24 at the Screening assessment.
  3. Subjects in whom imaging findings suggestive of Parkinsonism-plus syndrome are observed on PET and MRI performed at the Screening Visit, as assessed by the Investigator and/or a qualified imaging specialist.
  4. Subjects who do not meet the diagnostic criteria for Parkinson's disease dementia but present with major visual hallucinations, as judged by the Investigator.
  5. Subjects with drug-induced parkinsonism, confirmed by clinical history and/or medical records, and determined by the Investigator.
  6. Subjects who are judged by the investigator to be unsuitable for participation in this clinical trial.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Low dose (1.0 x 10^10 vg/patient)

IPS101A

The investigational product (IP) will be administered as a single dose. All subjects will receive stereotactic injections into the left and right substantia nigra of the midbrain, with one administration per side.

实验性的:High dose(2.0 x 10^10 vg/patient)

IPS101A

The investigational product (IP) will be administered as a single dose. All subjects will receive stereotactic injections into the left and right substantia nigra of the midbrain, with one administration per side.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Safety Evaluation: dose-limiting toxicity (DLT)
大体时间:Baseline to Week 8

Frequency and proportion of subjects who developed dose-limiting toxicity (DLT)

Baseline to Week 8
Safety Evaluation: Severity and frequency of reported adverse events
大体时间:Baseline to Week 52

Assess severity and frequency of reported adverse events

Baseline to Week 52
Safety Evaluation: clinically-relevant changes in laboratory testing assessed by medical personnel
大体时间:Baseline to Week 52

The clinical significance of laboratory test results after administration of a clinical trial drug is confirmed by comparing them with those before administration.

Baseline to Week 52
Safety Evaluation: clinically-relevant changes in physical exams assessed by medical personnel
大体时间:Baseline to Week 52

The results of the physical examination after administration of the clinical trial drug are compared with those before administration to determine whether clinically significant symptoms occur.

Baseline to Week 52

次要结果测量

结果测量
措施说明
大体时间
Change from Baseline in Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores (defined on/off)
大体时间:Baseline to Weeks 4, 12, 24, 36, and 52.

Each symptom is rated on a scale of 0 to 4, with higher scores indicating more severe Parkinson's disease.

Baseline to Weeks 4, 12, 24, 36, and 52.
Change from Baseline in Hoehn & Yahr stage (defined on/off)
大体时间:Weeks 1, 4, 12, 24, 36, and 52.

This scale is classified from 0 to 5, with a higher score indicating a more severe degree of Parkinson's disease.

Weeks 1, 4, 12, 24, 36, and 52.
Change from Baseline in Non-Motor Symptoms Scale for Parkinson's Disease (NMSS)
大体时间:Weeks 4, 12, 24, 36, and 52.

This scale is rated on a scale of severity (0-3 points) and frequency (1-4 points). A higher score indicates more severe Parkinson's disease.

Weeks 4, 12, 24, 36, and 52.
Change from Baseline in Parkinson's Disease Questionnaire (PDQ-39) scores
大体时间:Weeks 4, 12, 24, 36, and 52

The scale consists of 800 points, and a higher score indicates a lower quality of life.

Weeks 4, 12, 24, 36, and 52
Distribution evaluation of IPS101A (AAV9 vector distribution evaluation)-CSF
大体时间:Baseline to Week 52

After IP administration, the detection of AAV genome was measured using q-PCR.

Baseline to Week 52
Distribution evaluation of IPS101A (AAV9 vector distribution evaluation)-blood
大体时间:Baseline to Week 52

After IP administration, the detection of AAV genome was measured using q-PCR.

Baseline to Week 52
Evaluation of humoral (anti-AAV9 antibodies) and cellular (IFN-γ activity) immune responses to AAV9
大体时间:Baseline to Week 52

After IP administration, the detection of AAV genome was measured using ELISA

Baseline to Week 52
Assessment of AAV9 shedding in biological specimens-urine
大体时间:Baseline to Week 52

After IP administration, the detection of AAV genome was measured using q-PCR.

Baseline to Week 52

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月13日

初级完成 (估计的)

2028年6月30日

研究完成 (估计的)

2028年12月31日

研究注册日期

首次提交

2025年11月17日

首先提交符合 QC 标准的

2026年1月19日

首次发布 (实际的)

2026年1月27日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅